0bc3f029'); });
MOST READ ARTICLES
Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalitiesMartha M Eibl & Hermann M WolfVol. 7, No. 12
20 Aug 2015Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trialsMadan Jagasia, Robert Zeiser, Michael Arbushites, Patricia Delaite, Brian Gadbaw & Nikolas von BubnoffVol. 10, No. 5
10 Jan 2018Therapeutic anti-CD3 monoclonal antibodies: from bench to bedsideChantal Kuhn & Howard L WeinerVol. 8, No. 8
10 May 2016Neoepitopes as cancer immunotherapy targets: key challenges and opportunitiesCory A Brennick, Mariam M George, William L Corwin, Pramod K Srivastava & Hakimeh Ebrahimi-NikVol. 9, No. 4
17 Mar 2017Fostamatinib for persistent/chronic adult immune thrombocytopeniaAdrian Newland, Eun-Ju Lee, Vickie McDonald & James B BusselVol. 10, No. 1
2 Oct 2017CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemiaJun Liu, Xi Zhang, Jiang F Zhong & Cheng ZhangVol. 9, No. 13
16 Oct 2017
Tweets by FSG
MOST CITED ARTICLES
Toll-like receptor agonists in cancer therapySylvia AdamsVol. 1, No. 6
3 Nov 2009Therapeutic anti-CD3 monoclonal antibodies: from bench to bedsideChantal Kuhn & Howard L WeinerVol. 8, No. 8
10 May 2016CD73–adenosine: a next-generation target in immuno-oncologyDavid Allard, Bertrand Allard, Pierre-Olivier Gaudreau, Pavel Chrobak & John StaggVol. 8, No. 2
25 Jan 2016Antibody-targeted nanoparticles for cancer therapyFrancois Fay & Christopher J ScottVol. 3, No. 3
11 Mar 2011Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potentialKoen van de Ven & Jannie BorstVol. 7, No. 6
22 Jun 2015Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysisOmar Abdel-Rahman, Hesham ElHalawani & Mona FouadVol. 7, No. 11
29 Oct 2015Strategies for combining immunotherapy with radiation for anticancer therapySteven N Seyedin, Jonathan E Schoenhals, Dean A Lee, Maria A Cortez, Xiaohong Wang, Sharareh Niknam, Chad Tang, David S Hong, Aung Naing, Padmanee Sharma, James P Allison, Joe Y Chang, Daniel R Gomez, John V Heymach, Ritsuko U Komaki, Laurence J Cooper & James W WelshVol. 7, No. 9
27 Aug 2015Immune checkpoint inhibitor combinations in solid tumors: opportunities and challengesChrisann Kyi & Michael A PostowVol. 8, No. 7
28 Jun 2016Talimogene laherparepvec (T-VEC) for the treatment of advanced melanomaDouglas B Johnson, Igor Puzanov & Mark C KelleyVol. 7, No. 6
22 Jun 2015
